Loss narrows sharply. Dogwood Therapeutics, Inc. (NASDAQ: DWTX) reported a loss of $0.26 per share for Q4 2025, narrower than the estimated loss. The company, which remains pre-revenue as it advances its clinical pipeline, reported a loss of $6.29 per share in the year-ago quarter.
No revenue yet. The company did not generate revenue in Q4 2025, consistent with its status as a clinical-stage biotechnology firm. Trading volume reached 67,899 shares on the report, with the stock closing at $3.22 and a market capitalization of $98.8 million.
Analyst sentiment holds firm. The consensus rating distribution shows 1 Strong Buy and 1 Buy recommendation with no Hold or Sell ratings, unchanged over the past three months.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.